Characteristics of compensatory mutations in the rpoC gene and their association with compensated transmission of Mycobacterium tuberculosis

Abstract

The aim of this study was to characterize rpoC gene mutations in Mycobacterium tuberculosis (MTB) and investigate the factors associated with rpoC mutations and the relation between rpoC mutations and tuberculosis (TB) transmission. A total of 245 MTB clinical isolates from patients with TB in six provinces and two municipalities in China were characterized based on gene mutations through DNA sequencing of rpoC and rpoB genes, phenotyping via standard drug susceptibility testing, and genotypic profiling by mycobacterial interspersed repetitive unit-variable number tandem repeat (MIRU-VNTR) typing. Approximately 36.4% of the rifampin-resistant isolates harbored nonsynonymous mutations in the rpoC gene. Twenty-nine nonsynonymous single mutations and three double mutations were identified. The rpoC mutations at locus 483 (11.3%) were predominant, and the mutations at V483G, W484G, I491V, L516P, L566R, N698K, and A788E accounted for 54.5% of the total detected mutations. Fifteen new mutations in the rpoC gene were identified. Rifampin resistance and rpoB mutations at locus 531 were significantly associated with rpoC mutations. MIRU-VNTR genotype results indicated that 18.4% of the studied isolates were clustered, and the rpoC mutations were not significantly associated with MIRU-VNTR clusters. A large proportion of rpoC mutation was observed in the rifampicin-resistant MTB isolates. However, the findings of this study do not support the association of rpoC mutation with compensated transmissibility.

Keywords

tuberculosis / drug resistance / compensatory mutations / transmission

References

[1] Yang C, Shen X, Peng Y, Lan R, Zhao Y, Long B, Luo T, Sun G, Li X, Qiao K, Gui X, Wu J, Xu J, Li F, Li D, Liu F, Shen M, Hong J, Mei J, DeRiemer K, Gao Q. Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. Clin Infect Dis 2015; 61(2): 219–227

[2] Yang C, Luo T, Shen X, Wu J, Gan M, Xu P, Wu Z, Lin S, Tian J, Liu Q, Yuan Z, Mei J, DeRiemer K, Gao Q. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis 2017; 17(3): 275–284

[3] Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312(5782): 1944–1946

[4] Mariam DH, Mengistu Y, Hoffner SE, Andersson DI. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48(4): 1289–1294

[5] Knight GM, Colijn C, Shrestha S, Fofana M, Cobelens F, White RG, Dowdy DW, Cohen T. The distribution of fitness costs of resistance-conferring mutations is a key determinant for the future burden of drug-resistant tuberculosis: a model-based analysis. Clin Infect Dis 2015; 61(Suppl 3): S147–S154

[6] Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004; 10(10): 1117–1121

[7] Blower SM, Chou T. Modeling the emergence of the ‘hot zones’: tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004; 10(10): 1111–1116

[8] Tang K, Sun H, Zhao Y, Guo J, Zhang C, Feng Q, He Y, Luo M, Li Y, Sun Q. Characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Sichuan in China. Tuberculosis (Edinb) 2013; 93(1): 89–95

[9] Brandis G, Pietsch F, Alemayehu R, Hughes D. Comprehensive phenotypic characterization of rifampicin resistance mutations in Salmonella provides insight into the evolution of resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2015; 70(3): 680–685

[10] Hughes D, Brandis G. Rifampicin resistance: fitness costs and the significance of compensatory evolution. Antibiotics (Basel) 2013; 2(2): 206–216

[11] Brandis G, Wrande M, Liljas L, Hughes D. Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol Microbiol 2012; 85(1): 142–151

[12] Maisnier-Patin S, Andersson DI. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol 2004; 155(5): 360–369

[13] Brandis G, Hughes D. Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J Antimicrob Chemother 2013; 68(11): 2493–2497

[14] de Vos M, Müller B, Borrell S, Black PA, van Helden PD, Warren RM, Gagneux S, Victor TC. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 2013; 57(2): 827–832

[15] Li QJ, Jiao WW, Yin QQ, Xu F, Li JQ, Sun L, Xiao J, Li YJ, Mokrousov I, Huang HR, Shen AD. Compensatory mutations of rifampin resistance are associated with transmission of multidrug-resistant Mycobacterium tuberculosis Beijing genotype strains in China. Antimicrob Agents Chemother 2016; 60(5): 2807–2812

[16] Liu Q, Zuo T, Xu P, Jiang Q, Wu J, Gan M, Yang C, Prakash R, Zhu G, Takiff HE, Gao Q. Have compensatory mutations facilitated the current epidemic of multidrug-resistant tuberculosis? Emerg Microbes Infect 2018; 7(1): 98–105

[17] Reed MB, Pichler VK, McIntosh F, Mattia A, Fallow A, Masala S, Domenech P, Zwerling A, Thibert L, Menzies D, Schwartzman K, Behr MA. Major Mycobacterium tuberculosis lineages associate with patient country of origin. J Clin Microbiol 2009; 47(4): 1119–1128

[18] Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, Bifani P, Kurepina N, Kreiswirth B, Sola C, Rastogi N, Vatin V, Gutierrez MC, Fauville M, Niemann S, Skuce R, Kremer K, Locht C, van Soolingen D. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44(12): 4498–4510

[19] Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2011; 44(1): 106–110

[20] Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, Kaur D, Posey JE, Plikaytis B, Oggioni MR, Gardy JL, Johnston JC, Rodrigues M, Tang PK, Kato-Maeda M, Borowsky ML, Muddukrishna B, Kreiswirth BN, Kurepina N, Galagan J, Gagneux S, Birren B, Rubin EJ, Lander ES, Sabeti PC, Murray M. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 2013; 45(10): 1183–1189

[21] Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, Harris SR, Bentley SD, Parkhill J, Nejentsev S, Hoffner SE, Horstmann RD, Brown T, Drobniewski F. Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res 2012; 22(4): 735–745

[22] Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, Bryant J, Parkhill J, Nejentsev S, Horstmann RD, Brown T, Drobniewski F. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 2014; 46(3): 279–286

[23] Feng JY, Jarlsberg LG, Salcedo K, Rose J, Janes M, Lin SG, Osmond DH, Jost KC, Soehnlen MK, Flood J, Graviss EA, Desmond E, Moonan PK, Nahid P, Hopewell PC, Kato-Maeda M. Clinical and bacteriological characteristics associated with clustering of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2017; 21(7): 766–773

[24] Yun YJ, Lee JS, Yoo JC, Cho E, Park D, Kook YH, Lee KH. Patterns of rpoC mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Tuberc Respir Dis (Seoul) 2018; 81(3): 222–227

[25] Levin BR, Perrot V, Walker N. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 2000; 154(3): 985–997

[26] Moura de Sousa J, Balbontín R, Durão P, Gordo I. Multidrug-resistant bacteria compensate for the epistasis between resistances. PLoS Biol 2017; 15(4): e2001741

[27] Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312(5782): 1944–1946

[28] Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2009; 15(Suppl 1): 66–68

[29] Lane WJ, Darst SA. Molecular evolution of multisubunit RNA polymerases: structural analysis. J Mol Biol 2010; 395(4): 686–704

[30] Opalka N, Brown J, Lane WJ, Twist KA, Landick R, Asturias FJ, Darst SA. Complete structural model of Escherichia coli RNA polymerase from a hybrid approach. PLoS Biol 2010; 8(9): e1000483

[31] Chen YY, Chang JR, Wu CD, Yeh YP, Yang SJ, Hsu CH, Lin MC, Tsai CF, Lin MS, Su IJ, Dou HY. Combining molecular typing and spatial pattern analysis to identify areas of high tuberculosis transmission in a moderate-incidence county in Taiwan. Sci Rep 2017; 7(1): 5394

[32] Zaw MT, Emran NA, Lin Z. Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J Infect Public Health 2018; 11(5): 605–610

Acknowledgements

This work was supported by the National Science and Technology Major Project (No. 2018ZX10103001) and the National Basic Research Program of China (No. 2014CB744403).

Compliance with ethics guidelines

Shengfen Wang, Yang Zhou, Bing Zhao, Xichao Ou, Hui Xia, Yang Zheng, Yuanyuan Song, Qian Cheng, Xinyang Wang, and Yanlin Zhao declare that they have no conflict of interest. This study was approved by the ethical review board of the Chinese Center for Disease Control and Prevention, and informed consent was obtained from all individual participants involved in this study.

RIGHTS & PERMISSIONS

2019 Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature